Responding to the clopidogrel warning by the US food and drug administration: real life is complicated.
作者信息
Roden Dan M, Shuldiner Alan R
出版信息
Circulation. 2010 Aug 3;122(5):445-8. doi: 10.1161/CIRCULATIONAHA.110.973362. Epub 2010 Jun 28.
Abstract
摘要
相似文献
1
Responding to the clopidogrel warning by the US food and drug administration: real life is complicated.回应美国食品药品监督管理局发出的氯吡格雷警告：现实生活很复杂。
Circulation. 2010 Aug 3;122(5):445-8. doi: 10.1161/CIRCULATIONAHA.110.973362. Epub 2010 Jun 28.
2
Clopidogrel: to test or not to test? That is the question--still.
Clin Chem. 2011 May;57(5):659-61. doi: 10.1373/clinchem.2010.158709. Epub 2011 Mar 14.
3
Clopidogrel poor metabolizers may need alternative to standard regimen.
Am J Health Syst Pharm. 2010 May 15;67(10):779-80. doi: 10.2146/news100036.
4
Pharmacogenomics of clopidogrel: evidence and perspectives.氯吡格雷的药物基因组学：证据与展望。
Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18.
5
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.临床药物基因组学实施联盟 CYP2C19（细胞色素 P450-2C19）基因型和氯吡格雷治疗指南。
Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29.
6
CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.CYP2C19和ABCB1基因与氯吡格雷的个体化治疗
Pharmacogenomics. 2011 Feb;12(2):141-4. doi: 10.2217/pgs.10.211.
7
ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.美国心脏病学会基金会/美国心脏协会氯吡格雷临床警报：应对美国食品药品监督管理局“黑框警告”：美国心脏病学会基金会临床专家共识文件特别工作组和美国心脏协会的报告
Circulation. 2010 Aug 3;122(5):537-57. doi: 10.1161/CIR.0b013e3181ee08ed. Epub 2010 Jun 28.
8
Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.药物遗传学检测：对氯吡格雷和华法林心血管治疗的影响
Cardiovasc Ther. 2010 Jun;28(3):135-8. doi: 10.1111/j.1755-5922.2010.00176.x.
9
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.经皮冠状动脉介入治疗后标准剂量与高剂量氯吡格雷的比较
JAMA. 2011 Jun 22;305(24):2520; author reply 2521-2. doi: 10.1001/jama.2011.842.
10
Clopidogrel: a case for indication-specific pharmacogenetics.氯吡格雷：一种针对适应症特异性的药物遗传学的案例。
Clin Pharmacol Ther. 2012 May;91(5):774-6. doi: 10.1038/clpt.2012.21.
引用本文的文献
1
Computational drug-drug interaction prediction mediated by CYP450 isoforms of Ilaprazole coadministered with clopidogrel.由伊拉普利与氯吡格雷共同给药时CYP450同工型介导的药物-药物相互作用的计算预测。
Future Sci OA. 2024 May 20;10(1):FSO966. doi: 10.2144/fsoa-2023-0277. eCollection 2024.
2
P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis.经皮冠状动脉介入治疗后急性冠状动脉综合征患者使用P2Y12抑制剂单药治疗与传统双联抗血小板治疗的Meta分析
Pharmaceuticals (Basel). 2023 Feb 3;16(2):232. doi: 10.3390/ph16020232.
3
Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying loss of function allele.替格瑞洛与氯吡格雷治疗携带功能缺失等位基因的冠心病患者的比较。
J Thorac Dis. 2022 Jul;14(7):2591-2601. doi: 10.21037/jtd-22-740.
4
Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications.孕期选择性5-羟色胺再摄取抑制剂的药代动力学：临床及研究意义
Front Pharmacol. 2022 Feb 25;13:833217. doi: 10.3389/fphar.2022.833217. eCollection 2022.
5
Clinical Outcomes and Sustainability of Using Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后使用基于基因型的抗血小板治疗的临床结果和可持续性。
Circ Genom Precis Med. 2018 Apr;11(4):e002069. doi: 10.1161/CIRCGEN.117.002069.
6
The effect of enoxaparin and clopidogrel on survival of random skin flap in rat animal model.依诺肝素和氯吡格雷对大鼠动物模型随机皮瓣存活的影响。
World J Plast Surg. 2012 Jul;1(2):64-70.
7
Pharmacogenomics of anti-platelet and anti-coagulation therapy.抗血小板和抗凝治疗的药物基因组学。
Curr Cardiol Rep. 2013 Jul;15(7):381. doi: 10.1007/s11886-013-0381-3.
8
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.临床相关 CYP2C 基因型和单倍型的多种族分布。
Pharmacogenomics J. 2013 Aug;13(4):369-77. doi: 10.1038/tpj.2012.10. Epub 2012 Apr 10.
9
Pharmacogenetics in type 2 diabetes: potential implications for clinical practice.2 型糖尿病的药物遗传学：对临床实践的潜在影响。
Genome Med. 2011 Nov 29;3(11):76. doi: 10.1186/gm292.
10
Pharmacogenomics: the genetics of variable drug responses.药物基因组学：药物反应变异性的遗传学
Circulation. 2011 Apr 19;123(15):1661-70. doi: 10.1161/CIRCULATIONAHA.109.914820.
本文引用的文献
1
The path to personalized medicine.个性化医疗之路。
N Engl J Med. 2010 Jul 22;363(4):301-4. doi: 10.1056/NEJMp1006304. Epub 2010 Jun 15.
2
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy.常见 CYP2C19 基因变异对慢性氯吡格雷治疗抗血小板作用的单独及交互影响。
J Thromb Haemost. 2010 Aug;8(8):1685-93. doi: 10.1111/j.1538-7836.2010.03921.x. Epub 2010 May 21.
3
Genotyping: one piece of the puzzle to personalize antiplatelet therapy.基因分型：实现个体化抗血小板治疗的拼图之一。
J Am Coll Cardiol. 2010 Jul 6;56(2):112-6. doi: 10.1016/j.jacc.2010.04.008. Epub 2010 May 13.
4
DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.DNA、药物和战车：美国 FDA 十年的药物基因组学
Pharmacogenomics. 2010 Apr;11(4):507-12. doi: 10.2217/pgs.10.16.
5
Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.氯吡格雷与质子泵抑制剂同时使用的结果：一项队列研究。
Ann Intern Med. 2010 Mar 16;152(6):337-45. doi: 10.7326/0003-4819-152-6-201003160-00003.
6
Omeprazole and clopidogrel: Should clinicians be worried?奥美拉唑和氯吡格雷：临床医生是否应该担忧？
Cleve Clin J Med. 2010 Feb;77(2):113-6. doi: 10.3949/ccjm.77a.09173.
7
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.细胞色素 2C19*17 等位基因变异、血小板聚集、出血事件和氯吡格雷治疗的冠状动脉支架置入患者的支架血栓形成。
Circulation. 2010 Feb 2;121(4):512-8. doi: 10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18.
8
Finding the missing heritability of complex diseases.寻找复杂疾病中缺失的遗传力。
Nature. 2009 Oct 8;461(7265):747-53. doi: 10.1038/nature08494.
9
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.细胞色素P450 2C19基因与氯吡格雷治疗的抗血小板作用及临床疗效的相关性
JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.
10
Can we override clopidogrel resistance?我们能否克服氯吡格雷抵抗？
Circulation. 2009 Jun 2;119(21):2854-7. doi: 10.1161/CIRCULATIONAHA.108.857722.
Zotero 插件